OBN BioTuesday: What’s New in Antimicrobial Resistance – is there light at the end of the tunnel?
The development of resistance to antimicrobials threatens to reverse the changes in public health that have occurred over the last 70 years or so. This is a global problem. While it is tempting to feel relatively comfortable with the situation, living as we do in the Western World, unless antimicrobial resistance (AMR) is tackled, it is very likely at some point to wreak havoc here too. Who now doesn’t regard the risk of a hospital acquired infection in themselves, a friend or a relative as a significant possibility? Or who now is not more concerned over minor cuts and grazes?
AMR is a much-discussed topic, and this edition of our BioTuesday series aims to provide attendees a better understanding of a range of issues, including the factors holding the development of new medicines back and how the field will develop.
Our speakers will discuss matters such as:
- The background to the crisis of AMR
- Has the situation worsened due to a lack of education and early action?
- What are the latest government policies around AMR – is this enough?
- What is the government and private funding landscape like for AMR research?
- What role does Machine Learning plan in the research of potential solutions to this crisis?
- Where does the UK stand compared to the rest of the world?
- How does the use of antibiotics in farming impact the problem, and what is the farming industry doing to make the required changes?
- What needs to change to get big pharma engaged?
- Is a combination approach the answer to AMR?
17:30 Registration & Networking
18:00 Welcome & Introductions
John Harris, CEO, OBN
Geoff Davison, CEO, BioNow
Chris Doherty, Managing Director, Alderley Park
18:15 Keynote Presentations
Dr Peter Jackson, Executive Director, AMR Centre
Dr Fiona Marston, Director of the Centre of Excellence in Infectious Diseases Research
Dr Richard Fitzgerald, Director of The Royal Liverpool and Broadgreen University Hospitals NHS Trust
Dr Peter Warn, SVP Anti-infective Discovery, Evotec
19:15 Company Presentations
Dr Deborah O'Neil, CEO, NovaBiotics
Dr Fiona Rudkin, CEO, mycoBiologics
Heather Graz, Commercial Development Manager, Neem Biotech
Conrad Lichtenstein, CSO, Nemesis Bioscience
Neill Gingle, Head of Research, metaLinear
William Rhys-Williams, Senior Director of Operations, Destiny Pharma
Clive Mason, Senior Director - Anti-infectives Research, Summit Therapeutics
20:25 Q&A with speakers and audience, hosted by Chris Doherty
20:40 Networking with drinks and canapes served
Alderley Park Conference Centre, Nether Alderley, Macclesfield, SK10 4TG
OBN Members - Complimentary
R&D companies - Complimentary
PHD Students & Research Scientists - Complimentary
Non Members, Non R&D Companies - £50+VAT
This event is kindly co-promoted by BIONOW